Last Update Time:
13-Mar-2025 16:00:00
ISIN:
INE901L01018
Sector:
Healthcare
Symbol:
APLLTD
Alembic Pharmaceuticals Limited
₹821.05
₹15.15
(1.88%)
▲
Prev. Close
₹805.90
Open
₹813.20
Close
₹827.35
Range
₹780.00 - ₹862.10
High
₹836.00
Low
₹800.25
Ind. Close
₹0.00
VWAP
₹823.31
The current stock price of Alembic Pharmaceuticals Limited is ₹821.05, with a target price range between ₹780.00 and ₹862.10. The stock has experienced a price change of ₹15.15 (1.88%), reflecting recent market volatility.
Today's opening price was ₹813.20, while the previous close stood at ₹805.90.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Alembic Pharmaceuticals Limited Price Chart
Alembic Pharmaceuticals Limited Pre Open Market Overview: 13-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 813.2
- Previous Close Price: 805.9
- Change: 7.30%
- Total Traded Volume: 201
- Total Buy Quantity: 1,672
- Total Sell Quantity: 794
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 801.90 | 10.00 | 0.00 |
| 802.00 | 1.00 | 0.00 |
| 802.75 | 1.00 | 0.00 |
| 805.00 | 2.00 | 0.00 |
| 806.00 | 79.00 | 0.00 |
| 813.20 | 0.00 | 3.00 |
| 813.25 | 0.00 | 10.00 |
| 813.30 | 0.00 | 16.00 |
| 813.90 | 0.00 | 8.00 |
| 813.95 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1672
Total Sell Quantity: 794
Shareholding Patterns of Alembic Pharmaceuticals Limited
Key Trade Statistics of Alembic Pharmaceuticals Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.20 |
| Traded Value (₹ Cr.) | 9.91 |
| Total Market Cap (₹ Cr.) | 16,138.82 |
| Free Float Market Cap (₹ Cr.) | 4,578.94 |
| Impact cost | 0.09 |
| Quantity Traded | 120,379.00 |
| Deliverable Quantity | 53,855.00 |
| % of Quantity to Traded | 44.74 |
| Security VaR | 14.32 |
| Index VaR | N/A |
| VaR Margin | 14.32 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 17.82 |
| Face Value | 2 |
Key Price Statistics of Alembic Pharmaceuticals Limited
The 52-week high for Alembic Pharmaceuticals Limited was ₹1,303.90, recorded on 09-Oct-2024. On the other hand, the 52-week low stands at ₹725.20, with the lowest value recorded on 03-Mar-2025.
The upper band for trading is ₹967.05, and the lower band is ₹644.75. The price band is 20%.
The stock's daily volatility stands at 2.23, while the annualized volatility is 42.60. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (09-Oct-2024) | 1,303.90 |
| 52 Week Low (03-Mar-2025) | 725.20 |
| Upper Band | 967.05 |
| Lower Band | 644.75 |
| Price Band (%) | 20 |
| Daily Volatility | 2.23 |
| Annualised Volatility | 42.60 |
| Tick Size | 0.05 |
Key Securities Statistics of Alembic Pharmaceuticals Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 20-Sep-2011 |
| Adjusted P/E | 27.45 |
| Symbol P/E | 26.99 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Alembic Pharmaceuticals Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Alembic Pharmaceuticals Limited
| Subject | Date |
|---|---|
| General Updates | 07-Mar-2025 |
| Copy of Newspaper Publication | 06-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 19-Feb-2025 |
| General Updates | 14-Feb-2025 |
| Copy of Newspaper Publication | 13-Feb-2025 |
| Notice Of Shareholders Meetings-XBRL | 12-Feb-2025 |
| Shareholders meeting | 12-Feb-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 11-Feb-2025 |
Corporate Actions of Alembic Pharmaceuticals Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Dividend - Rs 11 Per Share | 15-Jul-2024 |
| 2 | Dividend - Rs 8 Per Share | 28-Jul-2023 |
| 2 | Interim Dividend - Rs 10 Per Share | 17-Aug-2022 |
| 2 | Annual General Meeting/Dividend - Rs 14 Per Share | 19-Jul-2021 |
| 2 | Interim Dividend - Rs 7 Per Share Special Dividend - Rs 3 Per Share | 16-Mar-2020 |
| 2 | Annual General Meeting/Dividend Rs 5.50/- | 18-Jul-2019 |
| 2 | Annual General Meeting/Dividend- Rs 4 Per Share (Purpose Revised) | 18-Jul-2018 |
| 2 | Annual General Meeting/Dividend -Rs 4/- Per Share | 11-Jul-2017 |
| 2 | Annual General Meeting/Dividend - Rs 4/- Per Share | 20-Jul-2016 |
| 2 | Annual General Meeting/ Dividend - Rs 3.50/- Per Share | 22-Jul-2015 |
| 2 | Annual General Meeting / Dividend - Rs 3/- Per Share | 17-Jul-2014 |
| 2 | Annual General Meeting And Dividend Rs.2.50 Per Share | 29-Jul-2013 |
| 2 | Annual General Meeting / Dividend Rs 1.40 Per Share | 31-Jul-2012 |
Board Meetings of Alembic Pharmaceuticals Limited
Financial Results of Alembic Pharmaceuticals Limited
Company Directory of Alembic Pharmaceuticals Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.alembicpharmaceuticals.com | Registered Office | Alembic Road, Vadodara | VADODARA |
| www.alembicpharmaceuticals.com | Transfer Agent | MUFG Intime India Pvt. Ltd. "Geetakunj" 1, Bhakti Nagar Society, Behind ABS Tower, Old Padra Road | VADODARA |
Insider Trading of Alembic Pharmaceuticals Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Chirayu Ramanbhai Amin HUF | 38912524 | Buy |
| 7(2) | Chirayu Ramanbhai Amin HUF | 5925290 | Buy |
| 7(2) | Chirayu Ramanbhai Amin HUF | 3423686 | Buy |
| 7(2) | Chirayu Ramanbhai Amin HUF | 778630 | Buy |
| 7(2) | Chirayu Ramanbhai Amin HUF | 8129010 | Buy |
| 7(2) | - | 20860901 | Buy |
| 7(2) | Chirayu Ramanbhai Amin HUF | 0 | Sell |
| 7(2) | Satori Trust | 0 | Buy |
| 7(2) | Chirayu Ramanbhai Amin HUF | 0 | Sell |
| 7(2) | Gallup Trust | 0 | Buy |
| 7(2) | Inaaya Shaunak Amin | 0 | Buy |
| 7(2) | Naintara Shaunak Amin | 0 | Buy |
| 7(2) | Krupa Shaunak Amin | 0 | Buy |
| 7(2) | Barkha Pranav Amin | 0 | Buy |
| 7(2) | ALEMBIC LIMITED | 28467334 | Buy |
| 7(2) | Shreno Engineering Limited | 70818 | Buy |
| 7(2) | ALEMBIC LIMITED | 14452826 | Buy |
| 7(2) | ALEMBIC LIMITED | 49701806 | Buy |
| 7(2) | ALEMBIC LIMITED | 97743500 | Buy |
| 7(2) | Mr. Chirayu Ramanbhai Amin as Managing Trustee on behalf of CRA Family Trust | 78336 | Buy |
Annual Reports of Alembic Pharmaceuticals Limited
Investor Complaints of Alembic Pharmaceuticals Limited
Event Calendar of Alembic Pharmaceuticals Limited
| Purpose | Details |
|---|---|
| Results/Dividend | Inter alia, to transact following business : (1) To consider and approve Audited Financial statements of the Company for the Financial year ended March 31, 2012; (2) To recommend dividend for the Financial Year ended March 31, 2012. |
| Results/Dividend | Inter alia, to transact following business : (1) To consider and approve Audited Financial statements of the Company for the Financial year ended March 31, 2013; (2) To consider and recommend dividend for the Financial Year ended March 31, 2013. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended June 30, 2013. |
| Board meeting Rescheduled | The Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on October 30, 2013 inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended on September 30, 2013. The Company has now informed the Exchange that the aforesaid Board Meeting has been rescheduled and will now be held on October 25, 2013. |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended on September 30, 2013. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended December 31, 2013. Further, the trading window shall remain closed from January 19, 2014 to January 23, 2014 for the above purpose. |
| Results | inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended December 31, 2013. Further the trading window shall remain closed from 19-1-2014 to 23-1-2014 for the above purpose. |
| Results | APLLTD : 28-APR-2014 : inter alia to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31, 2014. Further it is informed that the trading window shall remain closed from April 25, 2014 to April 29, 2014 for the above purpose. The company has provided details of trading window period as per Prohibition of Insider Trading Regulations, 1992 issued by SEBI wherein when the trading window is closed, the employees/directors shall not trade in the company s securities in such period". |
| Results/Dividend | The Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on April 28, 2014 inter alia to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31, 2014. The Company has now informed the Exchange that the Board will also consider recommendation of dividend on the Equity Shares of the Company for the Financial Year 2013-2014, if any.(purpose revised) |
| Results | Inter alia, to consider and approve the Unaudited Financial Results of the Company for the Quarter ended June 30, 2014.Further, the trading window shall remain closed from July 25, 2014 to July 29, 2014 for the above purpose. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended September 30, 2014. The trading window shall remain closed from October 17, 2014 to October 21, 2014 for the above purpose. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended December 31, 2014. |
| Results/Dividend | inter alia, to transact following business: (1). To consider and approve Audited Financial Results of the Company for the Financial year ended March 31, 2015 (2). To consider and recommend dividend on Equity Shares, if any, for the Financial Year ended March 31, 2015. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended On June 30, 2015. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended September 30,2015. |
| Results | To consider Unaudited Financial Results of the Company for the quarter ended on December 31, 2015. |
| Results/Dividend | inter alia, to transact the following business: 1. To consider and approve Audited Financial Results of the Company for the financial year ended 31st March, 2016.2. To consider and recommend dividend on Equity Shares, if any, for the financial year ended 31st March, 2016. |
| Results | To consider Unaudited Financial Results of the Company for the quarter ended on June 30, 2016. Further, the Exchange is hereby informed that the trading window shall remain closed from July 26, 2016 to July 31, 2016 for the above purpose. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2016. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months period ended on December 31, 2016. |
| Results/Dividend | inter alia, to transact the following business: 1. To consider and approve Audited Financial Results of the Company for the financial year ended March 31, 2017. 2. To consider and recommend dividend on Equity Shares, if any, for the financial year ended March 31, 2017. |
| Results | inter- alia to consider and approve Unaudited Financial Results of the Company for the quarter ended June 30, 2017. |
| Results/Others | inter to consider and approve Unaudited Financial Results for the quarter and half year ended on September 30, 2017. |
| Results | Inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter and nine months period ended on December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2018 and other business matters |
| Fund Raising | To consider the proposal for issue of Non-Convertible Debentures on Private Placement Basis |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2018 and other business matters |
| Fund Raising | To consider Fund Raising |
| Other business matters | Inter alia to consider and approve the issue and allotment of Unsecured Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 350 Crores on Private Placement Basis. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2018 and other business matters |
| Other business matters | Inter-alia to consider and approve the issue and allotment of Unsecured Listed Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 150 Crores on Private Placement Basis under Tranche III, Subject to bidding by the eligible investors on the Electronic Book Platform (EBP) provided by National Stock Exchanges of India Limited on March 18, 2019 and acceptance by the Company. |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2019, dividend and other business matters |
| Fund Raising | To consider and approve the proposal for issue of Non-Convertible Debentures on Private Placement Basis. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2019 and other business matters |
| Financial Results/Other business matters | To consider and approve the unaudited financial results for the period ended September 30, 2019 and other business matters. |
| Financial Results/Other business matters | To consider and approve the unaudited financial results for the period ended December 31, 2019 and other business matters |
| Dividend | To consider interim dividend |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2020 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2020 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2020 and other business matters |
| Fund Raising | To consider Fund Raising |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2020 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2020 and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2021, dividend and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2021 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2021 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2021 and other business matters |
| Dividend | With reference to the captioned matter and in continuation to intimation dated 20th July, 2022 to consider Unaudited Financial Results for the quarter ended 30th June, 2022, the exchange is hereby informed that the Board of Directors of the Company at their meeting scheduled to be held on 4th August, 2022 shall also consider and approve re-classification of the final dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. We request you to kindly take the same on record. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2022 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2023 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2023 and other business matters |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend for the financial year 2023-24 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the quarter and half year ended September 30, 2024 |
| Financial Results/Other business matters | To consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2024 and other business matters |
Share Transfers of Alembic Pharmaceuticals Limited
Voting Results of Alembic Pharmaceuticals Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 22-JUL-2024 | AGM | To receive, condsider and adopt na)the Audited Standalone Financial Statements of the Company for the financial year ended 31st March, 2024 together with the Reports of the Board of Directors and the Auditors thereon; nb) the Audited Consolidated Financial Statements of the Company for the financial year ended 31st March, 2024 together with the Reports of the Auditors thereon. |
| 22-JUL-2024 | AGM | Ratification of Remuneration to the Cost Auditor for the financial year 2024-25. |
| 22-JUL-2024 | AGM | To appoint a Director in place of Mr. R. K. Baheti (DIN: 00332079), who retires by rotation and being eligible, offers himself for re-appointment. |
| 22-JUL-2024 | AGM | To declare Dividend on equity shares for the financial year 2023-24. |
| 12-MAY-2024 | Postal Ballot | Appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company |
| 12-MAY-2024 | Postal Ballot | Alteration in Articles of Association of the Company |
| 04-AUG-2023 | AGM | To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon |
| 04-AUG-2023 | AGM | Ratification of Remuneration to the Cost Auditor for the financial year 2023-24. |
| 04-AUG-2023 | AGM | Appointment of Mr. Jai Diwanji (DIN: 00910410) as an Independent Director of the Company. |
| 04-AUG-2023 | AGM | To appoint a Director in place of Mr. Pranav Amin (DIN: 00245099), who retires by rotation and being eligible, offers himself for re-appointment. |
| 04-AUG-2023 | AGM | To declare Dividend on equity shares for the financial year 2022-23. |
| 11-NOV-2022 | AGM | To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31st March, 2022 and the Reports of the Board of Directors and Auditors thereon. |
| 11-NOV-2022 | AGM | Ratification of Remuneration to the Cost Auditor for the financial year 2022-23. |
| 11-NOV-2022 | AGM | Re-appointment of Mr. Shaunak Amin (DIN: 00245523) as Managing Director of the Company. |
| 11-NOV-2022 | AGM | To appoint a Director in place of Mr. Shaunak Amin (DIN: 00245523), who retires by rotation and being eligible, offers himself for re-appointment. |
| 11-NOV-2022 | AGM | To confirm the payment of Interim Dividend on equity shares for the financial year 2021-22. |
| 14-JUN-2022 | Court Convened Meeting | Approval for the Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited with Alembic Pharmaceuticals Limited and their respective shareholders. |
| 17-MAR-2022 | Postal Ballot | Appointment of Mr. Ashok Barat (DIN: 00492930) as an Independent Director of the Company |
| 27-JUL-2021 | AGM | To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31st March, 2021 and the Reports of the Board of Directors and Auditors thereon |
| 27-JUL-2021 | AGM | To declare dividend on Equity Shares for the Financial Year 2020-21 |
FAQs on Alembic Pharmaceuticals Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.